Received Apr 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 3 | — | — |
administration of a pediatric dose of Hep B vaccine to an adult patient; administration of a pediatric dose of Hep B vaccine to an adult patient; This non-serious case was reported by a nurse via call center representative and described the occurrence of adult use of a child product in a 48-year-old male patient who received HBV (Engerix B pediatric) for prophylaxis. On 22-APR-2025, the patient received the 3rd dose of Engerix B pediatric. On 22-APR-2025, an unknown time after receiving Engerix B pediatric, the patient experienced adult use of a child product (Verbatim: administration of a pediatric dose of Hep B vaccine to an adult patient) and underdose (Verbatim: administration of a pediatric dose of Hep B vaccine to an adult patient). The outcome of the adult use of a child product and underdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date : 23-APR-2025 A nurse called to reported the administration of a pediatric dose of Hep B vaccine to an adult patient which led to adult use of child product and underdose. The nurse mentioned this was the third dose of the Hepatitis B series. The nurse could not provide the brand name nor the lot number of the vaccine but confirmed it was a GSK vaccine. The nurse asked for recommendations on this situation.